• Our results add to previously published data on the contribu

  2025-02-08

  

  Our results add to previously published data on the contribution of ALDH3A1 to the optical properties of the cornea. Specifically, the study by Nees et al. (2002) was among the first to examine whether ALDH3A1 serves as a structural component in the cornea and similarly to lens crystallins. Their ex

• br The AHR functions in the immune system

  2025-02-08

  

  The AHR functions in the immune system – a tsunami of exciting findings The research of recent years has convincingly established an important function of the AHR in linking chemical environmental cues to immune responses [21,22], and reviewed in [1,23]. As a side effect, a view of the AHR as “Th

• Further evidence for action mechanism was provided by assays

  2025-02-08

  

  Further evidence for action mechanism was provided by assays using [3H]nisoxetine, a selective NET inhibitor used as standard radioligand for competitive binding experiments. The results showed dose-dependent blocking of [3H]nisoxetine binding by both xylazine and dexmedetomidine. Nisoxetine binds t

• Pioneering studies on the immunomodulatory role of adenosine

  2025-02-08

  

  Pioneering studies on the immunomodulatory role of adenosine date back to the early ‘70 s of last century (Fig. 1), when the critical role of this nucleoside in shaping the development and the activity of several immune cell populations was first established [[18], [19], [20], [21], [22]]. This then

• The enzyme mediated ATP sensing mechanism

  2025-02-08

  

  The enzyme-mediated ATP-sensing mechanism in zebrafish can be compared with previous studies in other animal species reporting that enzymatic conversion of chemicals in the peripheral olfactory organ results in either “activation” or “inactivation” of odorants and pheromones. In male silkmoth, the a

• PF also a dual Aurora A and Aurora

  2025-02-07

  

  PF-03814735, also a dual Aurora-A and Aurora-B inhibitor, was administered in a phase I dose escalation study in a 3-weekly K-7174 for 5 or 10 consecutive days [69], [70]. To date 25 patients have been included in 7 dose levels (5–100mg/day for 5 days). Using the 5-day schedule the MTD was defined

• In our bioinformatics analysis of

  2025-02-07

  

  In our bioinformatics analysis of proteins with increased SUMOylation upon treatment with MMC and HU, we found clusters of co-regulated proteins that are known to function together in the RS response. In addition to the ATR activation proteins, BRCA1 and BARD1, we also found Fanconi anemia proteins

• To enhance the accuracy of SEs in eliminating cancer

  2025-02-07

  

  To enhance the accuracy of SEs in eliminating cancer cells, the mAb recognized by specific ZD1839 hydrochloride on tumor cells were fused with SEs. Fab C215 or C242 fused with SEA promoted apoptosis in human colon carcinoma cells via Fas (Dohlsten et al., 1994, Litton et al., 1996). SEB-incorporate

• Plant tissues were thought to be natural sources containing

  2025-02-07

  

  Plant tissues were thought to be natural sources containing different types of antioxidant compounds (tocopherols, ascorbic acid, carotenoids, and phenolic compounds). As a general classification, antioxidants were grouped as vitamins (ascorbic acid, tocopherols), carotenoids (condensed tannins, xan

• The subnuclear localizations of redox regulators is also lar

  2025-02-07

  

  The subnuclear localizations of redox regulators is also largely unknown. The potential role of thiol reductases as transcription regulators or DNA repair molecules may suggest an association to DNA. In this way, the presence of a zinc finger domain potentially involved in protein/DNA interactions o

• No starting dose adjustment is needed for mild or moderate

  2025-02-07

  

  No starting dose adjustment is needed for mild or moderate renal impairment and mild hepatic impairment (Child-Pugh A classification) though use in patients with severe hepatic impairment (Child-Pugh classification Class C, 10–15 points score) is not recommended.8, 9, 10, 13 Drug interaction & ad

• Expression of Twist and the

  2025-02-07

  

  Expression of Twist1 and the AR are increased by oxidative stress, but the change in the receptor (mRNA/protein) is lost after treatment with siRNAs that target Twist 1 (Shiota et al., 2010). Twist 1 was found to bind to E-boxes, 5′-CANNTG-3′, in the proximal promoter (−442 to +51 bp) and upstream r

• Critically we found that pre treatment with A monomer prepar

  2025-02-07

  

  Critically we found that pre-treatment with Aβ monomer preparations prevented the Aβ oligomer-induced aggregation of PrPC. These preparations contain a mixture of Aβ species and consequently it was not possible to identify the precise form of Aβ that is responsible for this effect. It is possible th

• Here we provide evidence that NO contributes

  2025-02-07

  

  Here, we provide evidence that NO contributes to changes in synaptic strength, but also offer an explanation as to why previous attempts to link NO to LTP have often failed. Our results describe a model by which cycling AMPARs, held in intracellular pools, are rapidly delivered to the membrane surfa

• Following activation of mGluRs GRIP stabilized AMPARs appear

  2025-02-07

  

  Following activation of mGluRs, GRIP-stabilized AMPARs appear to be the primary target for endocytosis. Consistent with this model, we find that using siRNA to reduce GRIP1/2 expression blocks the AMPAR internalization and the synaptic depression mediated by mGluRs. Reductions in GRIP1/2 expression,

15687 records 18/1046 page Previous Next First page 上5页 1617181920 下5页 Last page